Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
Retrieved on:
Tuesday, January 10, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Disease, Crigler–Najjar syndrome, Ageing, Institute of Liver and Biliary Sciences, Gene, Blood, Bilirubin, Toxicity, Muscular Dystrophy Association, AAV, Death, Safety, Academic Medical Center (Amsterdam), Nerve, Patient, Light, Research, Clinical trial, UGT1A1, Immunology, Pharmaceutical industry, Clamart
Genethon , a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has launched a pivotal clinical trial in Europe for treatment of Crigler-Najjar syndrome, a life threatening liver disease.
Key Points:
- Genethon , a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), has launched a pivotal clinical trial in Europe for treatment of Crigler-Najjar syndrome, a life threatening liver disease.
- “This new step demonstrates once again the excellence of the research conducted at Genethon, which is today one of the major players in gene therapy at the international level."
- Crigler-Najjar syndrome is a rare genetic liver disease characterized by abnormally high levels of bilirubin in the blood (hyperbilirubinemia).
- The gene therapy, administered intravenously, was designed by Genethon's Immunology and Gene Therapy of Liver Diseases team, led by Dr. Giuseppe Ronzitti.